Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Solta Medical,'s 3-Year RORE % for the quarter that ended in Sep. 2013 was 0.00%.
The industry rank for Solta Medical,'s 3-Year RORE % or its related term are showing as below:
FRA:NZ5's 3-Year RORE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -4.755 * Ranked among companies with meaningful 3-Year RORE % only.
Solta Medical, 3-Year RORE % Historical Data
The historical data trend for Solta Medical,'s 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Solta Medical,'s 3-Year RORE %
For the Medical Devices subindustry, Solta Medical,'s 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solta Medical,'s 3-Year RORE % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Solta Medical,'s 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Solta Medical,'s 3-Year RORE % falls into.
Solta Medical, 3-Year RORE % Calculation
Solta Medical,'s 3-Year RORE % for the quarter that ended in Sep. 2013 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2013 and 3-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Solta Medical, 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Solta Medical,'s 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Solta Medical, Inc. was incorporated in California on January 11, 1996 as Thermage, Inc. and reincorporated in Delaware on September 10, 2001. It designs, develops, manufactures and markets energy-based medical device systems for aesthetic applications. The Company markets its systems and treatment tips in the United States to physician practices primarily through a direct sales force and internationally in over 100 countries through both a network of distributors and direct sales force. Its customers consist mainly of dermatologists and plastic surgeons and its expanded customer base includes other specialties such as general and family practitioners, gynecologists, ophthalmologists and others. These systems are marketed under the brand names Fraxel and Thermage. It currently markets four Fraxel products: The re:store, re:store Dual, re:fine and re:pair. The Fraxel re:store, Fraxel re:store Dual and Fraxel re:fine laser platforms non-ablatively treat a range of applications that include wrinkles and fine lines, pigmentation, sun damage, uneven skin texture and melasma. The Company's Thermage systems consist of a radiofrequency (RF) generator with cooling capability, through the delivery of a coolant to protect the outer layer of the skin from over-heating, and a hand piece that, in conjunction with a treatment tip, regulates epidermis cooling and monitors treatment data. Its system includes a variety of single-use, disposable treatment tips that attach to the hand piece and are selected by physicians based on the procedure to be performed and the size of the area to be treated. The Company sells its Thermage and Fraxel systems to physicians in the United States primarily through a direct sales force of trained sales consultants. Its industry is subject to intense competition. It compete directly against laser and light-based skin rejuvenation products and procedures offered by companies such as Alma Laser, Cutera, Cynosure, Lumenis, Lutronic, Palomar Medical Technologies, Sciton and Syneron Medical. In addition, it compete against existing and emerging treatment alternatives such as cosmetic surgery, chemical peels, microdermabrasion, Botox, dermal fillers and collagen injections. The Company's Thermage and Fraxel systems are medical devices and are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration (FDA), as well as other federal and state regulatory bodies in the United States and laws and regulations of foreign authorities in other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:NZ5 has been successfully added to your 